JP2010526857A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526857A5 JP2010526857A5 JP2010507937A JP2010507937A JP2010526857A5 JP 2010526857 A5 JP2010526857 A5 JP 2010526857A5 JP 2010507937 A JP2010507937 A JP 2010507937A JP 2010507937 A JP2010507937 A JP 2010507937A JP 2010526857 A5 JP2010526857 A5 JP 2010526857A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- day
- active substance
- composition according
- diiodothyronine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 239000013543 active substance Substances 0.000 claims 20
- 229940088597 hormone Drugs 0.000 claims 11
- 239000005556 hormone Substances 0.000 claims 11
- CPCJBZABTUOGNM-LBPRGKRZSA-N 3,3'-diiodo-L-thyronine Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C(I)=C1 CPCJBZABTUOGNM-LBPRGKRZSA-N 0.000 claims 10
- ZHSOTLOTTDYIIK-UHFFFAOYSA-N 3,5-Diiodothyronine Chemical compound IC1=CC(CC(N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C=C1 ZHSOTLOTTDYIIK-UHFFFAOYSA-N 0.000 claims 8
- SXQVOFSDWXYIRP-ZDUSSCGKSA-N (2s)-2-azaniumyl-3-[4-(4-hydroxyphenoxy)-3-iodophenyl]propanoate Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C=C1 SXQVOFSDWXYIRP-ZDUSSCGKSA-N 0.000 claims 7
- 206010012601 diabetes mellitus Diseases 0.000 claims 6
- CPCJBZABTUOGNM-UHFFFAOYSA-N 3',3-diiodothyronine Natural products IC1=CC(CC(N)C(O)=O)=CC=C1OC1=CC=C(O)C(I)=C1 CPCJBZABTUOGNM-UHFFFAOYSA-N 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 5
- RUIUIJSMLKJUDC-ZDUSSCGKSA-N 3'-monoiodothyronine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C(I)=C1 RUIUIJSMLKJUDC-ZDUSSCGKSA-N 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 206010022489 Insulin Resistance Diseases 0.000 claims 3
- 201000001421 hyperglycemia Diseases 0.000 claims 3
- VSWSDTLXDWESGZ-AWEZNQCLSA-N (2s)-3-[4-(4-hydroxyphenoxy)phenyl]-2-(iodoamino)propanoic acid Chemical compound C1=CC(C[C@@H](C(=O)O)NI)=CC=C1OC1=CC=C(O)C=C1 VSWSDTLXDWESGZ-AWEZNQCLSA-N 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 231100000245 skin permeability Toxicity 0.000 claims 2
- 210000004003 subcutaneous fat Anatomy 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000035484 Cellulite Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 206010049752 Peau d'orange Diseases 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 230000036232 cellulite Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 208000020694 gallbladder disease Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 229940126701 oral medication Drugs 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 210000002374 sebum Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000001319 vasomotor rhinitis Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07290634 | 2007-05-16 | ||
| PCT/EP2008/056074 WO2008138993A1 (en) | 2007-05-16 | 2008-05-16 | New pharmaceutical compositions comprising diiodothyronine and their therapeutic use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010526857A JP2010526857A (ja) | 2010-08-05 |
| JP2010526857A5 true JP2010526857A5 (enExample) | 2011-06-23 |
Family
ID=38521888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010507937A Withdrawn JP2010526857A (ja) | 2007-05-16 | 2008-05-16 | ジヨードチロニンを含んでなる新規な医薬組成物及びその治療的使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110028554A1 (enExample) |
| EP (1) | EP2068858A1 (enExample) |
| JP (1) | JP2010526857A (enExample) |
| CA (1) | CA2687380A1 (enExample) |
| WO (1) | WO2008138993A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1992341A1 (en) * | 2007-05-16 | 2008-11-19 | Université Joseph Fourier | New pharmaceutical compositions comprising a thyroid hormon and their therapeutic use |
| US20120065267A1 (en) * | 2010-09-09 | 2012-03-15 | T*Amine, Llc | Compositions including 3,5-l-t2 and methods of use thereof |
| KR102105354B1 (ko) | 2012-08-20 | 2020-04-29 | 오츠카 세이야쿠 가부시키가이샤 | 당대사능의 측정 방법 및 그에 사용하는 조성물 |
| ES2754246T3 (es) | 2013-03-15 | 2020-04-16 | Otsuka Pharma Co Ltd | Composición para su uso en un método para medir la razón de combustión azúcar/ácido graso |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3067247A (en) * | 1958-08-19 | 1962-12-04 | Hoechst Ag | Process for preparing l(+)-3, 5-diiodothyronine |
| US4426453A (en) * | 1980-09-18 | 1984-01-17 | Amersham International Limited | Derivatives of iodothyronine compounds and their use in an assay for the free iodothyronine compounds |
| US5767227A (en) * | 1989-11-03 | 1998-06-16 | Lotus Biochemical Corp. | Iodothyronine polymers |
| US6221911B1 (en) * | 1995-06-07 | 2001-04-24 | Karo Bio Ab | Uses for thyroid hormone compounds or thyroid hormone-like compounds |
| US5635209A (en) * | 1995-10-31 | 1997-06-03 | Vintage Pharmaceuticals, Inc. | Stabilized composition of levothyroxine sodium medication and method for its production |
| US7163918B2 (en) * | 2000-08-22 | 2007-01-16 | New River Pharmaceuticals Inc. | Iodothyronine compositions |
| ITRM20030363A1 (it) * | 2003-07-24 | 2005-01-25 | Fernando Goglia | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse. |
-
2008
- 2008-05-16 US US12/600,109 patent/US20110028554A1/en not_active Abandoned
- 2008-05-16 CA CA002687380A patent/CA2687380A1/en not_active Abandoned
- 2008-05-16 WO PCT/EP2008/056074 patent/WO2008138993A1/en not_active Ceased
- 2008-05-16 EP EP08759706A patent/EP2068858A1/en not_active Withdrawn
- 2008-05-16 JP JP2010507937A patent/JP2010526857A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6807371B2 (ja) | 口を介する連続的薬物送達のためのデバイスおよび方法 | |
| RU2572692C2 (ru) | Сублингвальные композиции дексмедетомидина и способы их применения | |
| Wang et al. | Insulin glargine: a systematic review of a long-acting insulin analogue | |
| Ferrannini et al. | Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes | |
| EP2744572B1 (en) | Abuse-resistant mucoadhesive devices for delivery of buprenorphine | |
| BRPI0818687A2 (pt) | composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença. | |
| US20130072532A1 (en) | Topical transdermal dexmedetomidine compositions and methods of use thereof | |
| IL203747A (en) | Use of a steroid sex precursor in the manufacture of a 13mg dose or less for daily dosing through the vagina to treat vaginal diseases and a vaginal pharmacological preparation containing it | |
| JP2014528474A5 (enExample) | ||
| IL199005A0 (en) | Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method | |
| WO2007098479A3 (en) | Localized insulin delivery for bone healing | |
| IL192104A (en) | Formulation suitable for subcutaneous administration containing molecules of ctla4ig, sugar and liquid liquid pharmacist acceptable and its use in drug preparation | |
| TW200824693A (en) | Pharmaceutical compositions of clonazepam and methods of use thereof | |
| CL2007002347A1 (es) | Compuestos derivados de fenilo, piridina y quinolina; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de diabetes mellitus, trastornos en la tolerancia de la glucosa, obesidad, enfermedad de crohn, enferm | |
| MX2013011174A (es) | Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2. | |
| JP2010518164A5 (enExample) | ||
| JP2010526837A5 (enExample) | ||
| US20120295893A1 (en) | Compositions and methods of counteracting residual sedative effects of sleep/ hypnotic drugs | |
| Sangsuwan et al. | Randomized controlled trial of Tinospora crispa for additional therapy in patients with type 2 diabetes mellitus | |
| CN105263495A (zh) | α7烟碱型乙酰胆碱受体激动剂的应用 | |
| JP2008545715A5 (enExample) | ||
| JP2010526858A5 (enExample) | ||
| SI1880718T1 (sl) | Farmacevtski pripravki za oralno dajanje z nadzorovanim sproščanjem zdravila v majhne intestinke kolone in postopek njihove priprave | |
| JP2009534367A5 (enExample) | ||
| Spector et al. | The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria |